Human anti-ErbB2 immunoagents - ImmunoRNases and compact antibodies

FEBS Journal

Volumn 276, Issue 6, 2009, Pages 1527-1535

  De Lorenzo, Claudia ^a   D'Alessio, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antibodies; Antitumor drugs; Breast cancer; Cardiotoxicity; ErbB2; Herceptin; Immunoagents; Immunogenicity; ImmunoRNases; Immunotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBICIN; IMMUNOGLOBULIN G1; IMMUNORIBONUCLEASE; RECOMBINANT ANTIBODY; RIBONUCLEASE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN BINDING; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARDIOTOXICITY; DRUG DIFFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ANTIBODIES; HUMANS; RECEPTOR, ERBB-2; RIBONUCLEASES;

EID: 61349158561     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.06896.x     Document Type: Review

References (77)

1. Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A Rolfe M (2003) Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther 3, 107 121.
2. Trikha M, Yan L Nakada MT (2002) Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 13, 609 614.
3. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ et al. (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13, 3245 3260.
4. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J Johnson KS (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14, 309 314.
5. Winter G, Griffiths AD, Hawkins RE Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12, 433 455.
6. Hoogenboom HR Chames P (2000) Natural and designer binding sites made by phage display technology. Immunol Today 21, 371 378.
7. Nielsen UB Marks JD (2000) Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharm Sci Technol Today 3, 282 291.
8. Vaughan TJ, Osbourn JK Tempest PR (1998) Human antibodies by design. Nat Biotechnol 16, 535 539.
9. Klapper LN, Kirschbaum MH, Sela M Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77, 25 79.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707 712.
11. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K Yamamoto T (1986) Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6, 955 958.
12. Semba K, Kamata N, Toyoshima K Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82, 6497 6501.
13. Graus-Porta D, Beerli RR, Daly JM Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J 16, 1647 1655.
14. Ishida T, Tsujisaki M, Hanzawa Y, Hirakawa T, Hinoda Y, Imai K Yachi A (1994) Significance of erbB-2 gene product as a target molecule for cancer therapy. Scand J Immunol 39, 459 466.
15. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM et al. (1995) In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1, 73 81.
16. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC Marks JD (1998) Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 95, 6157 6162.
17. Poul MA, Becerril B, Nielsen UB, Morisson P Marks JD (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 301, 1149 1161.
18. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA D'Alessio G (2002) A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8, 1710 1719.
19. Pastan I, Hassan R, FitzGerald D Kreitman R (2007) Immunotoxin treatment of cancer. Annu Rev Med 58, 221 237.
20. Newton DL, Ilercil O, Laske DW, Oldfield E, Rybak SM Youle RJ (1992) Cytotoxic ribonuclease chimeras. Targeted tumoricidal activity in vitro and in vivo. J Biol Chem 267, 19572 19578.
21. Rybak S (1991) Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J Biol Chem 266, 21202 21207.
22. Newton DL, Xue Y, Boque L, Wlodawer A, Kung HF Rybak SM (1997) Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy. Protein Eng 10, 463 470.
23. Newton DL, Xue Y, Olson KA, Fett JW Rybak SM (1996) Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 35, 545 553.
24. Rybak S, Newton D, Mikulski SM, Viera A Youle RJ (1993) Cytotoxic onconase and ribonuclease A chimeras: comparison and in vitro characterization. Drug Deliv 1, 3 10.
25. Zewe M, Rybak SM, Dubel S, Coy JF, Welschof M, Newton DL Little M (1997) Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 3, 127 136.
26. Riordan JF (1997) Structure and function of angiogenin. In Ribonucleases: Structures and Functions (D'Alessio G Riordan JF, eds pp. 446 466. Academic Press, New York.
27. Snyder M Gleich G (1997) Eosinophil-associated ribonucleases. In Ribonucleases. Structures and Functions (D'Alessio G Riordan G, eds pp. 426 444. Academic Press, New York.
28. Pavlakis N Vogelzang NJ (2006) Ranpirnase - an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6, 391 399.
29. Braschoss S, Hirsch B, Dubel S, Stein H Durkop H (2007) New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo. Leuk Lymphoma 48, 1179 1186.
30. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM Rybak SM (2001) Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97, 528 535.
31. Arndt MA, Krauss J, Vu BK, Newton DL Rybak SM (2005) A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells. J Immunother 28, 245 251.
32. Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S Rybak SM (2005) Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. Biochem Biophys Res Commun 331, 595 602.
33. Rybak SM, Hoogenboom HR, Meade HM, Raus JC, Schwartz D Youle RJ (1992) Humanization of immunotoxins. Proc Natl Acad Sci USA 89, 3165 3169.
34. Landre JB, Hewett PW, Olivot JM, Friedl P, Ko Y, Sachinidis A Moenner M (2002) Human endothelial cells selectively express large amounts of pancreatic-type ribonuclease (RNase 1). J Cell Biochem 86, 540 552.
35. De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R D'Alessio G (2004) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64, 4870 4874.
36. De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L D'Alessio G (2007) Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 581, 296 300.
37. Dickson KA, Haigis MC Raines RT (2005) Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol 80, 349 374.
38. Riccio G, Borriello M, D'Alessio G De Lorenzo C (2008) A novel human antitumor dimeric immunoRNase. J Immunother 31, 440 445.
39. Piccoli R, Di Gaetano S, De Lorenzo C, Grauso M, Monaco C, Spalletti-Cernia D, Laccetti P, Cinatl J, Matousek J D'Alessio G (1999) A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. Proc Natl Acad Sci USA 96, 7768 7773.
40. Menzel C, Schirrmann T, Konthur Z, Jostock T Dubel S (2008) Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 111, 3830 3837.
41. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1, 118 129.
42. Yokota T, Milenic DE, Whitlow M Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52, 3402 3408.
43. Adams GP (1998) Improving the tumor specificity and retention of antibody-based molecules. In Vivo 12, 11 21.
44. Maack T, Johnson V, Kau ST, Figueiredo J Sigulem D (1979) Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 16, 251 270.
45. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE Schlom J (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82, 1191 1197.
46. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P Schlom J (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51, 6363 6371.
47. Hudson PJ Souriau C (2003) Engineered antibodies. Nat Med 9, 129 134.
48. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF III., Bookman MA, Fand I, Houston LL Weiner LM (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53, 4026 4034.
49. Nielsen UB, Adams GP, Weiner LM Marks JD (2000) Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 60, 6434 6440.
50. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R D'Alessio G (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91, 1200 1204.
51. Brambell FW (1966) The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2, 1087 1093.
52. Junghans RP (1997) Finally The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16, 29 57.
53. Shu L, Qi CF, Schlom J Kashmiri SV (1993) Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci USA 90, 7995 7999.
54. Demignot S, Pimm MV Baldwin RW (1990) Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts. Cancer Res 50, 2936 2942.
55. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL Schlom J (1993) Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 53, 3776 3783.
56. Cheng LS, Liu AP, Yang JH, Dong YQ, Li LW, Wang J, Wang CC Liu J (2003) Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). Cell Res 13, 35 48.
57. 125I-labeled anti-p185 antibodies in vitro and their biodistribution in vivo. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 21, 591 594.
58. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM Marks JD (2001) Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 251, 123 135.
59. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P D'Alessio G (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26, 1890 1895.
60. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J et al. (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26, 78 83.
61. Stebbing J, Copson E O'Reilly S (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26, 287 290.
62. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26, 60 70.
63. Drebin JA, Link VC Greene MI (1988) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2, 387 394.
64. Cardoso F, Piccart MJ, Durbecq V Di Leo A (2002) Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3, 247 257.
65. Baselga J (2000) Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol 27, 27 32.
66. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783 792.
67. Sparano JA (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28, 20 27.
68. De Lorenzo C, Troise F, Cafaro V D'Alessio G (2007) Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. Br J Cancer 97, 1354 1360.
69. Troise F, Cafaro V, Giancola C, D'Alessio G De Lorenzo C (2008) Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. FEBS J 275, 4967 4979.
70. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE et al. (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65, 5907 5916.
71. Dorvillius M, Garambois V, Pourquier D, Gutowski M, Rouanet P, Mani JC, Pugniere M, Hynes NE Pelegrin A (2002) Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol 23, 337 347.
72. Damle NK, Doyle LV Bradley EC (1986) Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137, 2814 2822.
73. Grimm EA, Mazumder A, Zhang HZ Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155, 1823 1841.
74. Shi M, Xie Z, Feng J, Sun Y, Yu M, Shen B Guo N (2003) A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function. Biotechnol Lett 25, 815 819.
75. Shi M, Zhang L, Gu HT, Jiang FQ, Qian L, Yu M, Chen GJ, Luo Q, Shen BF Guo N (2007) Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo. Acta Pharmacol Sin 28, 1611 1620.
76. Xie Z, Guo N, Yu M, Hu M Shen B (2005) A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 296, 95 101.
77. Germain C, Campigna E, Salhi I, Morisseau S, Navarro-Teulon I, Mach JP, Pelegrin A Robert B (2008) Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. Protein Eng Des Sel 21, 665 672.